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Survivin is a gene that is widely expressed throughout the development of the normal mammalian embryo. Subcellular localisation of
Survivin to both the nucleus and cytoplasm has suggested multiple functional roles, including inhibition of cell death, especially as
demonstrated within a variety of malignant cell types, as well as regulation of the mitotic spindle checkpoint. The expression of
Survivin has been associated with an adverse clinical outcome in a large number of malignancies. However, nuclear Survivin
expression has been described as an independent variable of favourable prognosis in two large clinical studies of breast and gastric
carcinomas. Reports of Survivin expression in normal postnatal, differentiated tissues have been restricted to cell types with high
proliferative capacities, including vascular endothelium, endometrium, colonic epithelium, and activated lymphocytes. Prior to this
report, expression within the normal human brain had not been characterised. Here, we analyse the expression of Survivin in human
brain sections obtained from perinatal and paediatric autopsy cases. We report a strikingly high level of expression of Survivin within
normal ependyma and choroid plexus (CP). Analysis of corresponding neoplastic tissue in paediatric ependymomas and CP tumours
shows that expression of the nuclear form of Survivin correlates with morphologic tumour grade, with a loss of nuclear expression
associated with progressive cytologic anaplasia. This pattern of expression supports a hypothesis that Survivin plays a functional role in
normal ependymal growth and/or neural stem cell differentiation, and that abnormally low levels of expression of the nuclear form of
this protein may be a marker of more aggressive disease and/or higher morphologic grade in ependymal and CP tumours.
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Tumours of the central nervous system (CNS) are the most
common subset of solid tumours presenting in children less than
15 years of age (Heideman et al, 1997). The overall frequency of
these cancers is second only to acute lymphoblastic leukaemia
(ALL) of childhood; however, the overall survival and resulting
morbidity between these tumours differ tremendously. While
paediatric ALL is approaching 80% long-term survival, the average
survival of paediatric CNS tumours is only 45%, with the majority
of children in remission suffering frequent life-long physical and
neurologic deficits (Heideman et al, 1997). Although much work
has been accomplished in differentiating paediatric CNS tumours
histologically, little is still understood about their molecular
abnormalities. Those abnormalities characterised to date are often
distinct from those of adult brain tumours, a phenomenon that is
likely related to mutational events that occur during embryologic
development in paediatric tumours, within pathways essential for
cell death, proliferation, and differentiation (Biegel, 1997).
Survivin is a gene with structural homology to a family of genes
known as inhibitors of apoptosis (IAPs) (Li et al, 1998). It is widely
expressed in foetal tissues and is critical for the growth and
survival of the normal embryo (Uren et al, 2000). Genetically
engineered homozygous deletion of this gene in mice results in
death of the embryo early in development, between days 4 and 6 of
gestation (Uren et al, 2000). The normal cellular function of
Survivin is probably related to ensuring the accurate procession of
cell division, as it is expressed in a cell-cycle-dependent manner in
G2/M and has been localised to the kinetochore during the late
phase of mitosis (Skoufias et al, 2000). Controversy exists as to the
relationship between its antiapoptotic role, documented in
mammalian cell culture as well as in in vivo tumour models, and
its role as a chromosomal passenger protein in lower eukaryotes.
Multiple splice forms of Survivin have been described in normal
and tumour cells and Survivin has also been localised to multiple
subcellular compartments within the cell, including the nucleus
and cytoplasm, suggesting that it probably has more than one
function (Fortugno et al, 2002; Krieg et al, 2002; Mahotka et al,
2002a,b). Abnormally elevated levels of Survivin expression have
been reported in a variety of adult malignancies, and in vitro and
in vivo tumour studies are suggestive of Survivin playing an
effective role in preventing cell death in these tumours (reviewed
in Altieri, 2003). It has been proposed that Survivin represents an
ideal candidate for molecular-targeted therapy in tumours
expressing this gene, as its expression was originally reported to Received 22 May 2003; revised 4 August 2003; accepted 27 August 2003
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ybe absent in postnatal, differentiated tissues. Several recent
reports, however, show evidence of Survivin expression in specific
adult tissues. These have included vascular endothelial cells,
colonic epithelium, normal endometrium, and lymphocytes
(Konno et al, 2000; Gianani et al, 2001; Fukuda et al, 2002; Altieri,
2003). In addition, other investigators have shown that expression
of the nuclear form of Survivin in breast and gastric carcinomas is
an independent prognostic indicator of good prognosis in these
tumours, suggesting that a loss of nuclear Survivin expression may
play a role in tumour progression (Okada et al, 2001; Kennedy et al,
2003).
In the present study, we evaluated the protein expression of
Survivin by immunohistochemistry in nonmalignant brain tissue
from human perinatal and paediatric autopsy sections, and in
biopsies of nonmalignant paediatric brain tissue during surgery.
Interestingly, we found that normal ependymal cells and choroid
plexus (CP) epithelial cells strongly express Survivin both in the
nucleus and cytoplasm. We then examined the expression of
Survivin in corresponding neoplastic tissue, including various
well-described subtypes and grades of paediatric ependymomas
and CP tumours. The expression of Survivin was detectable in the
majority of tumours examined; however, the percentage of cells
with distinct nuclear staining correlated strongly and inversely
with morphologic tumour grade. This pattern of expression
supports the hypothesis that Survivin plays a functional role in
normal ependymal growth and/or neural stem cell differentiation,
and that abnormally low levels of expression of the nuclear form of
this protein may be a marker of disease aggression and/or
morphologic grade in ependymal and CP tumours.
MATERIALS AND METHODS
Patient selection
Children with brain tumours of ependymal and CP origin,
diagnosed and treated within the last 11 years at Columbus
Children’s Hospital, were selected from the pathology database,
based on their pathologic diagnoses and the availability of
formalin-fixed paraffin-embedded tumour material. Permission
from the Children’s Hospital IRB was granted for staining of slides
and clinical chart review on each case. A total of 14 ependymomas
(six myxopapillary (WHO grade I), five classic (WHO grade II),
and three anaplastic (WHO grade III)) and nine CP tumours (three
papillomas (WHO grade I), three ‘atypical’ papillomas (WHO
grade I–II), and three carcinomas (WHO grade III)) were
evaluated. Clinical follow-up was available on all cases, except
one myxopapillary ependymoma. Treatment at diagnosis was
based on histologic findings and extent of surgical resection and
included surgery, radiation, and/or chemotherapy. Diagnoses were
re-confirmed by clinicopathologic review by DRB for each case
prior to antibody staining. The diagnosis of anaplastic ependy-
moma was made based on a predominance of a hypercellular, less
well-differentiated component, together with increased mitotic
activity (Burger, 1994). An atypical papilloma was defined by
scattered mitotic activity, obvious cytologic atypia, increased
nuclear:cytoplasmic ratio, and focal multilayering of the epithe-
lium or stromal nests of the epithelium (Burger, 1994). Sections of
nonmalignant brain tissue (preterm and older paediatric) obtained
at autopsy and fixed within 24h of death, as well as from a surgical
case of a CP cyst from a patient without morphologic evidence of
neoplastic transformation, were also analysed for Survivin
expression.
Immunohistochemistry
Blocks of nonmalignant brain tissue, obtained at autopsy from a
22-week foetus and a 5-year-old child, respectively, were formalin-
fixed within 24h of death and re-cut immediately prior to antibody
staining. Diagnostic tissue blocks from a non-neoplastic CP cyst
and from malignant brain tissue were reviewed for tissue integrity
and degree of differentiation/atypia by the paediatric neuropathol-
ogist prior to selecting blocks for sectioning and antibody staining.
Those blocks with large amounts of necrosis and/or heat or
chemical injury related to either the surgical procedure or to a
delay in fixation were excluded from the analysis. Four slides were
cut from each nonmalignant and from each malignant block and
were stained with H&E, two different polyclonal anti-Survivin
antibodies, and normal rabbit serum as a negative control,
respectively. Normal brain sections were inclusive of regions from
the following brain areas: (1) frontal–parietal cortex and white-
matter, (2) basal ganglia/periventricular white matter, (3) hippo-
campus/temporal cortex, (4) midbrain, (5) pons, (6) medulla, (7)
cerebellum (cortex, white matter, and dentate nucleus), (8)
occipital cortex, (9) thalamus/hypothalamus, and (10) spinal cord
(cervical, thoracic, and lumbar).
Formalin-fixed, paraffin-embedded tissue sections were freshly
cut and immunostained for Survivin using two different polyclonal
anti-Survivin antibodies. One antibody, obtained from Novus
Biologicals (NB-500-201 K3), was used at a dilution of 1:300 for
each case. The other antibody, obtained from Santa Cruz (sc-
10811), was used at a dilution of 1:400. Each antibody was
pretested on tumours known to express Survivin, including human
breast carcinomas and melanomas, to determine appropriate
antibody dilutions. Negative controls, performed with normal
rabbit Ig as the primary antibody, were used to ensure the
specificity of staining.
Sections (4mm) from paraffin blocks were placed on glass slides
and baked overnight at 601C. Following passage through xylene
and graded alcohols, the sections were treated with 3% hydrogen
peroxide. Antigen retrieval was carried out by pressure-cooking in
citrate buffer, pH 6.0. The sections were then incubated overnight
with the polyclonal antibodies (or normal rabbit Ig) at 41C.
Sections were washed, and then incubated with a biotinylated
secondary anti-rabbit antibody (Biocare Medical) for 20min at
room temperature. Slides were then incubated with Streptavidin
HRP (Biocare Medical). After rinsing for 20min, slides were
treated with AEC (Amino-ethylcarbazole), and then counterstained
with haematoxylin.
Evaluation of immunohistochemistry results
Survivin immunoreactivity was evaluated semiquantitatively based
on the percentage of cells demonstrating nuclear and/or cytoplas-
mic immunohistochemical staining. Scoring was performed by the
paediatric neuropathologist (DRB) for each case. Staining was
assessed in 5–10 high-powered fields at  40 magnification. Slides
were assigned scores of 1 if o10% positive, 2 if o10–20%
positive, 3 if 21–50% positive, and 4 if 450% positive.
Western blot
Perinatal brain tissues obtained at autopsy from a 28-week
gestation age infant were frozen in dry ice, and grounded in a
cold mortar containing a small amount of dry ice. The powdered
brain tissue was then transferred to an Eppendorf tube. An equal
weight/volume of blending buffer (containing 10% SDS, 62.5mM
Tris pH 6.8, 5mM EDTA, 1mM PMSF) was added and cells were
further lysed using a Teflon pestle, and subsequently sonicated
three times for 10s using a Virsonic 300 sonicator (Virtis Corp.,
Gardiner, NY, USA) to homogenise large size DNA. Cell debris was
removed by centrifugation at 14K r.p.m. for 1min. The protein
concentration of the supernatant was determined by the BioRad
DC protein assay (BioRad Laboratories, Hercules, CA, USA).
Protein samples (50mg each) were separated by electrophoresis on
a 12% SDS–polyacrylamide gel. The separated proteins were
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ytransferred onto a nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA, USA) using a Bio-Rad Semi-dry Transfer Cell.
Survivin was detected using ECL Advance Western Blotting
Detection Kit according to the manufacturer’s instructions. Briefly,
the membrane was blocked in 20mM Tris-buffered saline (pH 7.6)
with 0.1% Tween (TBST) containing 2% (wv
 1) blocking powder
provided by the manufacturer at 41C overnight. The membrane
was incubated with a 1:5000 dilution of primary antibody (sc-
10811, Santa Cruz, CA, USA) for 1h at room temperature. The
membrane was then washed four times with TBST. HRP-
conjugated anti-mouse secondary antibody (Santa Cruz) at a
dilution of 1:5000 was added to the membrane and incubated at
room temperature for 30min. After four TBST washes, the blot was
incubated in detection reagent for 5min and exposed to a
HyperfilmtECLt film (Amersham Pharmacia Biotech, Buckin-
ghamshire, England). Human b-actin, an internal control, was
detected using a mouse monoclonal anti-b-actin antibody (Sigma,
St Louis, MO, USA).
RESULTS
Patient characteristics
Of the 14 patients with ependymomas, the ages at diagnosis ranged
from 3 to 20 years (mean¼9.2 years). Myxopapillary ependymo-
mas (six cases) were confined to the lower spinal cord (filum
region) in all cases. Intracranial ependymomas were localised to
the posterior fossa (six cases) and supratentorial region (two
cases). Anaplastic ependymomas were located in the supratentorial
region (two cases) and the posterior fossa (one case). Myxopapil-
lary ependymomas were treated with surgical resection only (3) or
resection followed by radiation (3). Treatment for intracranial
ependymomas included surgical resection alone (1) or surgery
followed by radiation and chemotherapy (seven cases). Follow-up
ranged from 1 to 10 years after initial diagnosis. Three patients
(two grade II ependymomas and one grade III ependymoma) died
of disease progression within 4 years of diagnosis.
Of the nine patients with CP tumours, three had grade I
papillomas, three had grade I–II (atypical) papillomas, and three
had grade III choroid plexus carcinomas (CPC). Ages at diagnosis
for the six patients with papillomas ranged from 4 days to 48
months (average 22.6 months). Ages at diagnosis for the patients
with CPCs were 17 months, 22 months, and 14 years. Patients with
grade I or grade II papillomas were treated with surgery alone. Two
patients with CPC were treated with surgery, radiation, and
chemotherapy. One patient with CPC died prior to initiation of
therapy. Another patient with a CPC died of disease progression.
The third patient with a CPC is alive, but is currently less than 1
year from diagnosis. All eight patients with CP papillomas (grade I
and II) remain alive without evidence of disease progression
(follow-up 2–11 years).
Immunohistochemical analysis
Diffusely strong Survivin staining of sections from normal brain
was observed in the ependymal cells lining the ventricular system,
and choroidal epithelial cells comprising the CP (Figure 1).
Choroid plexus cells from a non-neoplastic CP cyst stained
similarly (Figure 1D and H). Some normal neurons, including
neurons within the midbrain, cerebellar dentate nucleus, Purkinje
cells (Figure 1C and G), anterior horn cells of the spinal cord, and
meningoepithelial cells also variably expressed Survivin. Vascular
endothelial cells were diffusely positive for Survivin. Neurons
within the medulla, occipital cortex, hippocampus, and thalamus
were essentially negative for Survivin. Glial cells (oligodendrocytes
and astrocytes) generally lacked any Survivin staining (Figure 1C
and G). The pattern of Survivin staining in the ependymal,
choroidal, and selective neuronal cells was predominantly
cytoplasmic using the NB-2500-201K3 antibody, and was pre-
dominantly nuclear using the sc-10811 antibody (Figure 1A–D
compared with E–H).
The results of immunohistochemical staining of ependymomas
are shown in Table 1 and Figure 2. Five of six myxopapillary
tumours showed between 50 and 100% of nuclear positivity
for Survivin with the sc-10811 antisera. One of the six tumours
had a variable pattern of expression, with some regions of tumour
having greater than 90% of the nuclei positive and other
regions showing only 20–30% nuclear positivity. For the
grade II classic ependymomas, three of five had between 20
and 30% of the nuclei positive for Survivin and two of five
had over 50% of nuclei positive. In all three grade III anaplastic
Figure 1 Survivin expression in normal brain tissue using the sc-10811
antisera (A–D) and the NB-500-201K3 antisera (E–H). (A) choroid
plexus, (B) ependyma-fourth ventricle, (C) Purkinje neuron, (D) choroid
plexus cyst; (E) choroid plexus, (F) ependyma-fourth ventricle, (G)
Purkinje neurons, and (H) choroid plexus cyst. The sc-10811 antisera stain
the nuclear form, while the NB-500-201K3 antisera stain the cytoplasmic
form of Survivin.
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yependymomas, the percent of tumour nuclei staining positive was
only 10–20%.
The results of immunohistochemical staining of CP tumours are
shown in Table 1 and Figure 3. All grade I CP tumours had
50–100% of cell nuclei positive for Survivin. By contrast, the grade
I–II ‘atypical’ tumours had only 5–10% nuclear positivity and the
CPC had a maximum of 10% of nuclei staining positive (generally
o5%). The cells staining most intensely in both ependymal and
choroid tumours were those undergoing mitosis. Cytoplasmic
staining with the NB-500-201 antibody was equivalent (450%
cells) among all tumour grades. These results suggest an inverse
correlation between morphologic tumour grade and nuclear
Survivin staining, with higher grade tumours having less reactivity
than lower grade brain tumours.
Western blot analysis
A total of 50mg of total cellular protein, prepared from the cortex
and ependyma of a 28-week gestational age infant at autopsy, was
Table 1 Survivin staining scores in ependymomas (A) and choroid plexus tumours (B)
(A) Tumour grade Diagnosis Age (years) Nuclear Survivin staining Status
I Myxopapillary 16 4 Alive
I Myxopapillary 8 4 Unknown
I Myxopapillary 11 4/3 Alive, one recurrence
I Myxopapillary 12 4 Alive
I Myxopapillary 6 4 Alive
I Myxopapillary 14 4 Alive, drop met at dx
II Ependymoma 3 4 Died, progressive ds
II Ependymoma 6 3 Alive
II Ependymoma 4 3 Died, progressive ds
II Ependymoma 16 4 Alive
II Ependymoma 3 3 Alive
III Anaplastic 20 2 Alive, one recurrence
III Anaplastic 6 2 Died, progressive ds
III Anaplastic 4 2 Alive
(B) Tumour grade Diagnosis Age (months) Nuclear Survivin staining Status
I CPP 48 4 Alive
I CPP 20 4 Alive
I CPP 4 4 Alive w/ stable ds
I–II ACPP 48 1 Alive
I–II ACPP 0.13 1 Alive
I–II ACPP 16 1 Alive
III CPC 22 1 Died, progressive ds
III CPC 17 1 Died, progressive ds
III CPC 14 year 1/2 Alive (f/u o1 year)
1¼o10%; 2¼10–20%; 3¼21–50%; 4¼450% cells positive; CPP¼choroid plexus papilloma; ACPP¼atypical choroid plexus papilloma; CPC¼choroid plexus carcinoma;
DS¼disease; DX¼diagnosis.
Figure 2 Survivin expression in ependymomas using the sc-10811
antisera: (A) myxopapillary ependymoma, (B) grade II ependymoma, (C)
grade II ependymoma, and (D) anaplastic ependymoma. Figure 3 Survivin expression in choroid plexus tumours using the sc-
10811 antisera: (A) papilloma grade I, (B) atypical papilloma grade I–II
(low magnification), (C) atypical papilloma grade I–II (high magnification),
and (D) choroid plexus carcinoma.
Survivin expression in normal and neoplastic brain
RA Altura et al
1746





























ysubject to SDS electrophoresis on a 12% polyacrylamide
gel. Staining of blots was performed using the sc-10811 anti-
Survivin antibody and a b-actin antibody, as described. A specific
band at approximately 19kDa, consistent with the Survivin
protein, was observed. The expression of Survivin in ependymal
tissue was five- to 10-fold higher than that in the cortical tissue
(Figure 4). The small amount of ‘cortical’ Survivin detected is
likely derived from cortical blood vessel endothelium. These
results are consistent with the immunohistochemical staining of
the nonmalignant brain tissue described above, showing very high
levels of Survivin in ependymal cells when compared with other
areas of the brain.
DISCUSSION
Survivin is a gene with structural homology to the inhibitor of
apoptosis gene family and functions to prevent cell death in a
variety of tumour subtypes (Ambrosini et al, 1997; Li et al, 1998;
Altieri, 2003). It was originally reported that Survivin was normally
expressed at high levels in foetal tissue, but absent in normal adult,
differentiated cells (Ambrosini et al, 1997). Interestingly, our study
of normal human brain, using two different antibodies that
differentially detect nuclear and cytoplasmic Survivin protein
expression, shows that both variants are present at high levels
within the ependyma and CP of a 22-week foetus (essentially the
time of completion of ependymal differentiation) and an older
child. To our knowledge, this is the first report of Survivin
expression in normal human brain tissue. Our data suggest that
similar levels of Survivin expression, with a similar subcellular
localisation, exists among foetal and older paediatric brain tissue.
These results have many implications for understanding the
functional roles of Survivin in the prenatal and postnatal
development of the CNS and potentially for understanding the
functional role of the ependyma, a cellular domain whose function
is still incompletely understood.
In the normal adult mammalian brain, ependymal cells,
composed of a single uninterrupted layer of ciliated squamous to
columnar cells, comprise the lining of the cerebral ventricles and
the central canal of the spinal cord (Bruni, 1998). Growth and
differentiation of the ependymal lining occurs over a lengthy
period of foetal development, from about the fourth week of
gestation to week 22 in the human foetus (Bruni, 1998). The CP is a
highly specialised type of ependymal epithelium arising after
closure of the neural tube in the lateral, third, and fourth
ventricles, around week 7 (Dziegielewska et al, 2001). The function
of the ependyma is hypothesised to vary at different stages in the
lifetime of the animal, based on differential protein expression
analyses. Foetal ependyma plays a role in the differentiation and
cellular organisation of the developing CNS, including axon
guidance, motor neuron differentiation, transformation of radial
glia, and nutrient transport (Bruni, 1998). Adult ependyma plays a
role in regulating nutrient transport between the CSF and neuropil
via the ‘blood–brain barrier’ network; however, cellular and
molecular studies provide evidence that it may also be an
important region for the generation of new neurons (Morshead
and van der Kooy, 2001). The subgranular layer of the
hippocampal dentate gyrus and the forebrain periventricular
region (PVR) are the only two neurogenic regions that have been
described in the adult mammalian brain (Alvarez-Buylla et al,
2001). Controversy still exists as to the exact cellular origin of the
neural stem cell in the PVR; however, cell–cell interactions within
the subventricular zone and the ependymal layer are likely critical
for the growth and maintenance of these cells (Alvarez-Buylla et al,
2001). The expression of Survivin within the ependyma of normal
human brain, as shown by our group, is intriguing in the context
of a region that might be critical for the support of neural stem cell
growth. As a genetic disruption of Survivin directed exclusively to
neural tissue has not yet been reported, it is unknown as to what
effect the absence of this protein would incur on normal neural
development or in the context of neuronal injury.
Reports of Survivin expression in CNS tumours include
two studies of gliomas and astrocytomas (Chakravarti et al,
2002; Kajiwara et al, 2003), and one study of mixed subtypes
of CNS tumours (Sasaki et al, 2002). The former two studies
showed a correlation between high levels of Survivin and higher
grade tumours, as assayed by Western blot and reverse
transcriptase polymerase chain reaction (RT–PCR). In the latter
study of mixed CNS subtypes, the authors were unable to
demonstrate a correlation between Survivin expression, as assayed
by IHC, and tumour grade. In retrospect, all these studies used
reagents that would predominantly detect the cytoplasmic form of
Survivin. The antibodies used in two of the studies detected
cytoplasmic forms of the protein, and the primers used for the
RT–PCR study detected only one isoform of Survivin known to be
cytoplasmic. Analysis of Survivin protein expression in our study
of paediatric ependymal and CP tumours showed that Survivin is
expressed in all morphologic grades of these tumours. Using two
different Survivin antisera, we were able to detect predominantly
nuclear and predominantly cytoplasmic forms of Survivin,
respectively. Although both antibodies had some overlapping
reactivity, each stained these subcellular regions with varying
opposing intensity. Interestingly, the percent of nuclei staining
positive using the sc-10811 antisera was lower in morphologically
higher grade, less differentiated brain tumours (both ependymal
and CP), than the percent staining positive in the lower grade
tumours. This implies, functionally, that the selective loss of
expression of the nuclear form of Survivin may play a role in
tumour progression or anaplasia. These data are consistent with
that of recent publications of Survivin expression in breast and
gastric carcinomas, which demonstrated that lower nuclear
expression of Survivin was an independent prognostic indicator
of poor prognosis (Okada et al, 2001; Kennedy et al, 2003). As the
number of cases in our study was not large enough to assess the
impact of nuclear Survivin staining as an independent prognostic
factor in this subset of brain tumours, we cannot defend its use as a
marker for clinical outcome at this time. Our study does support a
potential use for the sc-10811 antibody in determining or helping
to confirm the morphologic grades of ependymomas and choroidal
tumours, as these particular brain tumours are notoriously
difficult to grade on the basis of histology alone (Burger, 1994).
Our data are not inconsistent with the findings of other studies
that identify high cytoplasmic expression of Survivin as a
prognostic factor in therapeutically resistant tumours, as results
here using the NB-500-201 antibody show that high levels of
cytoplasmic Survivin are expressed in higher grade ependymomas
and CPC. The percent of cells with cytoplasmic staining, however,
did not correlate with tumour grade in our study, consistent with
Figure 4 Survivin and b-actin protein expression in normal human
ependyma and cortex.
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ythe results in CNS tumours described previously (Sasaki et al,
2002).
As discussed in detail in a recent publication of Survivin
expression in breast carcinomas, as well as in several intracellular
localisation studies of Survivin protein, multiple pools of Survivin
exist within transformed cells and these likely have different
functions (Fortugno et al, 2002; Mahotka et al, 2002b; Kennedy
et al, 2003). Several different splice variants of Survivin also exist
(Survivin, Survivin delta Ex 3, and Survivin-2B), as illustrated in
Figure 5. These have been shown to be transcribed at variable
levels within tumour cells and to have varying degrees of
antiapoptotic activity (Mahotka et al, 2002a,b). Intracellular
localisation of the Survivin isoforms identified that the delta Ex
3 mutant localises exclusively to the nucleus and that Survivin and
Survivin-2B localise to the cytoplasm (Mahotka et al, 2002b;
Rodriguez et al, 2002). The delta Ex3 isoform has a novel C-
terminal amino-acid sequence within which resides a nuclear
localisation signal (NLS) (Mahotka et al, 2002b; Rodriguez et al,
2002). Interestingly, mutation studies of Survivin identified that its
cytoplasmic localisation results from its active export from the
nucleus and imply that the biological characteristics of Survivin
itself within tumour cells might account for the clinical properties
of the tumour (Rodriguez et al, 2002). Cytoplasmic Survivin has
been characterised as antiapoptotic, as requiring post-translational
modification by phosphorylation of a threonine residue for
apoptotic inhibition, and as associating with microtubules
(O’Connor et al, 2002). Nuclear Survivin has been proposed to
function as a kinetochore-associated, chromosomal passenger
protein, which may serve a role in maintaining the integrity of the
mitotic spindle (Uren et al, 2000). Disruption of this latter
function, either through the altered accumulation of the delta Ex3
form of Survivin or through an aberrant mechanism of Survivin
export from the nucleus, has huge implications for its role in
cancer and tumour progression, including the development of
aneuploidy and the accumulation of new genetic mutations.
In summary, in this work we have identified Survivin expression
in normal ependymal and choroidal brain cells as well as in their
corresponding neoplastic counterparts, and have suggested a role
for the quantitation of nuclear Survivin expression in the grading
of ependymal and choroidal neoplasia. Larger studies examining
the role of Survivin as an independent prognostic factor and its
functional role in these tumours as well as in normal brain tissue
during development and in response to injury need to be
undertaken.
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